About Tangent90
Why do we exist?
How do you solve the problem of managing copyright in a digital setting? It’s an issue that faces many industries, and pharma is no exception. For pharma customers’ content is king, with research being carried out to develop new products that address the ever-changing global health situation.

Leadership Team
Talented and diverse - Our team comprises innovators, developers, practical problem solvers and client services professionals, whose breadth of experience across a wide range of industries, enables us to deliver intuitive solutions to complex challenges.
Drive better access and ongoing engagement
The desired output from the research is new publications about the latest treatments or new data for existing products. Physicians want and trust peer-reviewed published data which gives them a complete picture of particular treatment options and the insight to support clinical decision making, however how that content is shared can pose a challenge to pharma.
The traditional approach to HCP engagement has changed – partially influenced by the pandemic but the evolution of digital approaches was already underway. Sharing third-party copyright published material, such as clinical papers has historically been fulfilled via a physical reprint. The content of each reprint belongs to the source publication and pharma are required to purchase licences per reprint to enable sharing of this content with HCPs.
Tangent90 enables pharma to drive better access and ongoing engagement with healthcare professionals using innovative digital solutions to distribute and support communication of scientific copyright content.

We go beyond expectation
The digital evolution has resulted in the ePrint – a digital copy of the published material with a more cost-efficient licence model. Our innovative solutions work seamlessly with the incumbent CRM, enabling reps to share scientific content in the form of an ePrint, capture consent and remain compliant whilst tracking every interaction.